The 1993 dengue 2 epidemic in North Queensland: a serosurvey and comparison of hemagglutination inhibition with an ELISA.

McBride, William John Hannan; Mullner, Helen; LaBrooy, Justin T.; Wronski, Ian

doi:10.4269/ajtmh.1998.59.457

Cited by 40 publications

(30 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While dengue occurrence is closely documented in some counties on the Australian coast, the serologic results from Charters Towers has contributed to uncertainty over the inland extent of the disease in Queensland [54]. Only the governments of Australia, New Caledonia and the Solomon Islands report dengue case numbers publicly.…”

Section: Resultsmentioning

confidence: 99%

Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus

et al. 2012

View full text Add to dashboard Cite

BackgroundDengue is a growing problem both in its geographical spread and in its intensity, and yet current global distribution remains highly uncertain. Challenges in diagnosis and diagnostic methods as well as highly variable national health systems mean no single data source can reliably estimate the distribution of this disease. As such, there is a lack of agreement on national dengue status among international health organisations. Here we bring together all available information on dengue occurrence using a novel approach to produce an evidence consensus map of the disease range that highlights nations with an uncertain dengue status.Methods/Principal FindingsA baseline methodology was used to assess a range of evidence for each country. In regions where dengue status was uncertain, additional evidence types were included to either clarify dengue status or confirm that it is unknown at this time. An algorithm was developed that assesses evidence quality and consistency, giving each country an evidence consensus score. Using this approach, we were able to generate a contemporary global map of national-level dengue status that assigns a relative measure of certainty and identifies gaps in the available evidence.ConclusionThe map produced here provides a list of 128 countries for which there is good evidence of dengue occurrence, including 36 countries that have previously been classified as dengue-free by the World Health Organization and/or the US Centers for Disease Control. It also identifies disease surveillance needs, which we list in full. The disease extents and limits determined here using evidence consensus, marks the beginning of a five-year study to advance the mapping of dengue virus transmission and disease risk. Completion of this first step has allowed us to produce a preliminary estimate of population at risk with an upper bound of 3.97 billion people. This figure will be refined in future work.

show abstract

Section: Resultsmentioning

confidence: 99%

Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Patients were classified as dengue-naïve (primary infection) or dengue-immune (secondary infection) based on the pre-existing IgG titer measured in the <72 h sample using the commercially available PanBio indirect IgG ELISA kit (37). Data obtained with our in-house E protein ELISAs in Figure 1 showed that titers specific for E protein increased rapidly between the first (<72 h) and the second time point (4–7 days).…”

Section: Resultsmentioning

confidence: 99%

Dengue Serotype Cross-Reactive, Anti-E Protein Antibodies Confound Specific Immune Memory for 1 Year after Infection

et al. 2014

View full text Add to dashboard Cite

Dengue virus has four serotypes and is endemic globally in tropical countries. Neither a specific treatment nor an approved vaccine is available, and correlates of protection are not established. The standard neutralization assay cannot differentiate between serotype-specific and serotype cross-reactive antibodies in patients early after infection, leading to an overestimation of the long-term serotype-specific protection of an antibody response. It is known that the cross-reactive response in patients is temporary but few studies have assessed kinetics and potential changes in serum antibody specificity over time. To better define the specificity of polyclonal antibodies during disease and after recovery, longitudinal samples from patients with primary or secondary DENV-2 infection were collected over a period of 1 year. We found that serotype cross-reactive antibodies peaked 3 weeks after infection and subsided within 1 year. Since secondary patients rapidly produced antibodies specific for the virus envelope (E) protein, an E-specific ELISA was superior compared to a virus particle-specific ELISA to identify patients with secondary infections. Dengue infection triggered a massive activation and mobilization of both naïve and memory B cells possibly from lymphoid organs into the blood, providing an explanation for the surge of circulating plasmablasts and the increase in cross-reactive E protein-specific antibodies.

show abstract

“…ELISA testing allows detection of all serotypes (DEN-1–4) and has a similar performance as the hemagglutination test, considered to be the gold standard for indirect serologic diagnosis of DENV infection [33]. Besides, ELISA testing for DENV may also detect cross-reactive antibodies to other flaviviruses, such as West Nile virus, whose circulation has been reported in Madagascar [10].…”

Section: Discussionmentioning

confidence: 99%

Seroepidemiology of Dengue Virus in Mayotte, Indian Ocean, 2006

Sissoko¹,

Ezzedine

Giry³

et al. 2010

PLoS ONE

View full text Add to dashboard Cite

BackgroundAlthough Dengue virus (DENV) circulation had been documented in neighbouring South-western Indian Ocean Islands, its presence in Mayotte is poorly characterised. To address this issue, we aimed to assess the seroprevalence of dengue IgG antibodies (DENV-IgG Ab) among the population and to investigate potential associations with individual and household characteristics.Methods/Principal FindingsIn November–December 2006 we conducted a cross-sectional serologic survey in Mayotte among 1,154 inhabitants aged ≥2 years by using a multistage cluster random sampling method. The overall prevalence of DENV-specific IgG antibodies (ELISA) was 22.73% (95% CI, 18.16–27.31). The age-specific seroprevalence increased with age (χ2 for trend = 11.86, P<0.0006), and was linked with previous known outbreaks in this region. In multivariate analysis, older age, being born in the Comoros and living in a household with a low socioeconomic index were positively associated with DENV IgG antibody positivity.ConclusionsThese findings document substantial prior exposure of the population of Mayotte to DENV and highlight the risk of severe illness due to the possibility of sequential DENV infections. Further investigations characterizing current DENV circulation patterns and associated serotypes are needed.

show abstract

The 1993 dengue 2 epidemic in North Queensland: a serosurvey and comparison of hemagglutination inhibition with an ELISA.

Cited by 40 publications

References 15 publications

Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus

Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus

Dengue Serotype Cross-Reactive, Anti-E Protein Antibodies Confound Specific Immune Memory for 1 Year after Infection

Seroepidemiology of Dengue Virus in Mayotte, Indian Ocean, 2006

Contact Info

Product

Resources

About